Replimune Group, Inc. (REPL) income statement

REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31

Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30

$21.89−0.09 (-0.41%)

Close on Nov 13, 2026Market cap $2.08BP/E –Yield –

Replimune Group, Inc. income statement

Annual Quarterly TTM

Periods

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 CY2025 2026-03-31	FY 2025 CY2024 2025-03-31	FY 2024 CY2023 2024-03-31	FY 2023 CY2022 2023-03-31	FY 2022 CY2021 2022-03-31	FY 2021 CY2020 2021-03-31	FY 2020 CY2019 2020-03-31	FY 2019 CY2018 2019-03-31	FY 2018 CY2017 2018-03-31	FY 2017 CY2016 2017-03-31
Research & Development	221	189	175	127	80	57	39	22	14	6.94
Selling, General & Admin	99	72	–	–	–	–	–	–	–	–
General & Administrative	–	72	60	51	39	23	17	8.77	5.71	2.71
Operating Expenses	320	262	235	177	118	80	56	31	19	9.65
Operating Income	-320	-262	-235	-177	-118	-80	-56	-31	-19	-9.65
Interest Expense	6.80	5.78	4.50	1.96	0	0.82	0.73	–	–	–
Interest & Investment Income	14	21	23	10	0.39	0.92	2.42	2.59	0.29	0.03
Other Non-Operating Income	5.43	15	19	3.08	0.28	-0.92	3.57	0.11	-0.47	1.94
Asset Impairment Charges	0.19	0	–	–	–	–	–	–	–	–
Pretax Income	-314	-247	-215	-174	-118	-81	-53	-31	-20	-7.70
Income Tax Expense	-0.55	0.47	0.41	0.29	0	0	0	0	0	0
Income from Continuing Operations	-314	-247	-215	-174	-118	-81	–	–	–	–
Net Income incl. Noncontrolling Interests	-314	-247	-216	-174	-118	-81	-53	-31	-20	7.70
Net Income	-314	-247	-216	-174	-118	-81	-53	-31	-20	-7.70
Net Income to Common	-314	-247	-216	-174	-118	-81	-53	-31	-20	-7.70
EPS (Basic)(per share)	-3.38	-3.07	-3.24	-2.99	-2.26	-1.75	-1.54	-1.33	-3.96	-1.55
EPS (Diluted)(per share)	-3.38	-3.07	-3.24	-2.99	-2.26	-1.75	-1.54	-1.33	-3.96	-1.55
Shares Outstanding (Basic, Weighted)(shares)	93	81	67	58	52	46	34	23	4.98	4.97
Shares Outstanding (Diluted, Weighted)(shares)	93	81	67	58	52	46	34	23	4.98	4.97
EBITDA	-317	-258	-232	-175	-116	-78	-56	-31	-19	-9.53

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -107.9%

Financial strength

Current ratio: 7.11
Debt to equity: 0.49
Debt to assets: 26.7%
Cash to current liabilities: 675.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 10.13
Dividend yield: –

See a number that looks wrong?